<DOC>
	<DOCNO>NCT01782326</DOCNO>
	<brief_summary>This study ass efficacy , safety tolerability QVA149 patient moderate severe COPD .</brief_summary>
	<brief_title>QVA vs. Salmeterol/Fluticasone , 52-week Exacerbation Study , FLAME ( EFfect Indacaterol Glycopyronium Vs Fluticasone Salmeterol COPD Exacerbations )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<criteria>Written informed consent must obtain assessment perform Male female adult age ≥40 year Patients stable Chronic Obstructive Pulmonary Disease ( COPD ) accord current GOLD strategy ( GOLD 2011 ) Current exsmokers smoke history least 10 pack year . ( Ten packyears define 20 cigarette day 10 year , 10 cigarette day 20 year ) Patients postbronchodilator Forced Expiratory Volume one second ( FEV1 ) ≥25 &lt; 60 % predict normal value , postbronchodilator FEV1/FVC ( Forced Vital Capacity ) &lt; 0.70 day 28 . ( Post refers 1 hour sequential inhalation 84 µg ( equivalent dose ) ipratropium bromide 400 µg salbutamol ) A documented history least 1 COPD exacerbation previous 12 month require treatment systemic glucocorticosteroids and/or antibiotic Patients take stable COPD medication ( least 60 day ) prior day 28 Patients mMRC grade least 2 day 28 Pregnant nursing ( lactate ) woman , pregnancy define state female conception termination gestation , confirm positive hCG ( human Chorionic Gonadotropin ) laboratory test Women childbearing potential , defined woman physiologically capable become pregnant , unless use effective method contraception dose study treatment . Women consider postmenopausal child bear potential 12 month natural ( spontaneous ) amenorrhea appropriate clinical profile ( e.g . age appropriate , history vasomotor symptom ) surgical bilateral oophorectomy ( without hysterectomy ) tubal ligation least six week ago . In case oophorectomy alone , reproductive status woman confirm follow hormone level assessment consider child bear potential Patients Type I uncontrolled Type II diabetes Patients history long QT syndrome whose QTc measure day 28 ( Fridericia method ) prolong ( &gt; 450 m male female ) confirm central assessor . These patient rescreened Patients clinically significant ECG abnormality prior randomization . ( These patient rescreened ) Patients clinically significant laboratory abnormality screen Patients clinically significant renal , cardiovascular ( limited unstable ischemic heart disease , NYHA Class III/IV leave ventricular failure , myocardial infarction ) , arrhythmia ( see patient atrial fibrillation ) , neurological , endocrine , immunological , psychiatric , gastrointestinal , hepatic , hematological abnormality could interfere assessment efficacy safety study treatment Patients paroxysmal ( e.g . intermittent ) atrial fibrillation exclude Patients persistent atrial fibrillation define continuous atrial fibrillation least 6 month control rate control strategy ( i.e. , selective beta blocker , calcium channel blocker , pacemaker placement , digoxin ablation therapy ) least 6 month may consider inclusion . In patient , atrial fibrillation must present prerandomization visit , rest ventricular rate &lt; 100/min . At screen atrial fibrillation must confirm central reading Patients contraindicate treatment , history reactions/ hypersensitivity follow inhaled drug , drug similar class component thereof : anticholinergic agent , long short act beta2 agonist , sympathomimetic amine , lactose excipients trial medication Patients history malignancy organ system , treat untreated , within past 5 year whether evidence local recurrence metastasis , exception localize basal cell carcinoma skin Patients narrowangle glaucoma , symptomatic benign prostatic hyperplasia bladderneck obstruction moderate severe renal impairment urinary retention . Benign Prostatic Hyperplasia ( BPH ) patient stable treatment consider Patients achieve acceptable spirometry result screen accordance American Thoracic Society ( ATS ) /European Respiratory Society ( ERS ) criteria acceptability ( one retest may perform patient n't meet acceptability criterion ) Patients COPD exacerbation require treatment antibiotic and/or systemic corticosteroid and/or hospitalization 6 week prior screen Patients develop COPD exacerbation severity ( mild/moderate/severe ) screen treatment eligible permit rescreened minimum 6 week resolution COPD exacerbation Patients respiratory tract infection within 4 week prior screen Patients develop respiratory tract infection screen prior treatment eligible , permit rescreened 4 week resolution respiratory tract infection Patients require long term oxygen therapy prescribe &gt; 12 hour per day Patients history asthma Patients onset respiratory symptom , include COPD diagnosis prior age 40 year Patients blood eosinophil count &gt; 600/mm3 screen Patients allergic rhinitis use H1 antagonist intranasal corticosteroid intermittently ( treatment stable dose regimen permit ) Patients concomitant pulmonary disease ( e.g . lung fibrosis , sarcoidosis , interstitial lung disease , pulmonary hypertension ) Patients clinically significant bronchiectasis Patients diagnosis α1 antitrypsin deficiency Patients active pulmonary tuberculosis , unless confirm imaging longer active Patients pulmonary lobectomy lung volume reduction surgery lung transplantation Patients participate plan participate active phase supervise pulmonary rehabilitation program study . ( Maintenance program permit . ) Patients receive medication class list protocol Patients receive COPD related medication class specify protocol must undergo require washout period prior screen follow adjustment treatment program Use investigational drugs/devices ( approve unapproved ) time enrollment , within 30 day 5 halflives screen , whichever long Patients unable use electronic patient diary EXACT pro diary Patients unable use dry powder inhaler device , Metered Dose Inhaler ( MDI ) pressurize MDI ( rescue medication ) comply study regimen .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>COPD , QVA149 , FLAME ( EFfect Indacaterol Glycopyronium Vs Fluticasone salmeterol COPD Exacerbations )</keyword>
</DOC>